Phaseline

Companies › Clasp Therapeutics

Clasp Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CLSP-1025
HLA-A*02:01 specific T cell engager targeting p53 R175H mutation
TP53Phase 1Advanced Solid TumorDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06778863CLSP-1025Phase 1Advanced Solid TumorOncologyDec 2027

Targets

TP53 (1)

Companies with the same targets

SynerGene Therapeutics PMV Pharmaceuticals Kartos Therapeutics Precigen OSE Immunotherapeutics Changchun GeneScience Pharmaceutical Nutshell Therapeutics (Shanghai) Jacobio Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.